Treatment of Patients With Early Septic Shock and Bio-Adrenomedullin(ADM) Concentration > 70 pg/ml With ADRECIZUMAB

NCT03085758 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

301

Enrollment

INDUSTRY

Sponsor class

Conditions

Septic Shock

Interventions

BIOLOGICAL: Adrecizumab
BIOLOGICAL: Placebo

Sponsor

Adrenomed AG